HK1066470A1 - West nile vaccine - Google Patents
West nile vaccineInfo
- Publication number
- HK1066470A1 HK1066470A1 HK04109356.5A HK04109356A HK1066470A1 HK 1066470 A1 HK1066470 A1 HK 1066470A1 HK 04109356 A HK04109356 A HK 04109356A HK 1066470 A1 HK1066470 A1 HK 1066470A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- west nile
- nile vaccine
- vaccine
- west
- nile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30833401P | 2001-07-27 | 2001-07-27 | |
| PCT/US2002/023447 WO2003061555A2 (en) | 2001-07-27 | 2002-07-23 | West nile vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1066470A1 true HK1066470A1 (en) | 2005-03-24 |
Family
ID=27613166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK04109356.5A HK1066470A1 (en) | 2001-07-27 | 2004-11-26 | West nile vaccine |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US7153513B2 (sh) |
| EP (3) | EP1427444B1 (sh) |
| JP (2) | JP4718778B2 (sh) |
| KR (2) | KR20040028952A (sh) |
| CN (2) | CN1935258B (sh) |
| AU (1) | AU2002365244B2 (sh) |
| BE (1) | BE2014C006I2 (sh) |
| BR (1) | BRPI0211492B1 (sh) |
| CA (1) | CA2452545C (sh) |
| CY (1) | CY2014010I2 (sh) |
| DK (1) | DK1427444T3 (sh) |
| ES (1) | ES2435095T3 (sh) |
| FR (1) | FR14C0016I2 (sh) |
| HK (1) | HK1066470A1 (sh) |
| HR (1) | HRP20040195B1 (sh) |
| HU (2) | HU228690B1 (sh) |
| LU (1) | LU92348I2 (sh) |
| ME (1) | ME00491B (sh) |
| MX (1) | MXPA04000680A (sh) |
| NZ (3) | NZ570270A (sh) |
| PL (2) | PL220846B1 (sh) |
| PT (1) | PT1427444E (sh) |
| RS (1) | RS53184B (sh) |
| WO (1) | WO2003061555A2 (sh) |
| ZA (1) | ZA200401596B (sh) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| CA2452545C (en) * | 2001-07-27 | 2015-06-09 | Wyeth | West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus |
| EP1664786B1 (en) * | 2003-09-09 | 2014-11-12 | Idexx Laboratories, Inc. | Detection of west nile virus infection and vaccination |
| US7074555B2 (en) * | 2004-04-28 | 2006-07-11 | Idexx Laboratories, Inc. | Detection of West Nile Virus |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US7482017B2 (en) | 2004-09-09 | 2009-01-27 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
| WO2006107655A2 (en) * | 2005-04-01 | 2006-10-12 | Wyeth | Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| AU2006245734C1 (en) | 2005-05-12 | 2012-05-24 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| EP1724338A1 (en) * | 2005-05-19 | 2006-11-22 | Crucell Holland B.V. | Methods for the production of a whole-inactivated West Nile Virus vaccine |
| WO2006122964A1 (en) * | 2005-05-19 | 2006-11-23 | Crucell Holland B.V. | Methods for the production of a whole-inactivated west nile virus vaccine |
| NZ564375A (en) * | 2005-06-24 | 2010-02-26 | Intervet Int Bv | Inactivated chimeric flavivirus vaccines and related methods of use |
| BRPI0617735B1 (pt) * | 2005-10-19 | 2022-05-17 | University Of Florida Research Foundation Inc | Composições compreendendo vírus isolados, polinucleotídeos, ou polipeptídeos, construções de expressão, vacinas, kits para proteger um canino da infecção do vírus influenza, uso do vírus na preparação de composição farmacêutica bem como método in vitro para detecção de um vírus influenza que é capaz de infectar um animal canídeo |
| EP1941033A2 (en) * | 2005-10-20 | 2008-07-09 | Wyeth a Corporation of the State of Delaware | Compositions and methods for the treatment of canine influenza virus disease |
| US7767210B2 (en) * | 2005-12-14 | 2010-08-03 | The Board Of Regents Of The University Of Oklahoma | RNA virus vaccines and methods |
| WO2007141274A2 (en) | 2006-06-06 | 2007-12-13 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
| BRPI0820341B1 (pt) * | 2007-11-06 | 2021-11-09 | Zoetis Services Llc | Composição imunogênica para uso na proteção de um animal contra uma doença associada a uma cepa virulenta de mycoplasma hyopneumoniae |
| EP2293813A4 (en) | 2008-05-23 | 2012-07-11 | Univ Michigan | NANOEMULSION VACCINES |
| US9642908B2 (en) * | 2008-07-30 | 2017-05-09 | University Of Kentucky Research Foundation | Equine disease model for herpesvirus neurologic disease and uses thereof |
| NZ603854A (en) * | 2008-08-29 | 2015-03-27 | Boehringer Ingelheim Vetmed | West nile virus vaccine |
| AU2010303741A1 (en) * | 2009-10-07 | 2012-04-19 | Zoetis W Llc | Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof |
| CA3018230A1 (en) | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim Vetmedica, Inc. | Equine rhinitis b vaccine |
| CN103045544B (zh) * | 2011-10-17 | 2015-01-14 | 华中农业大学 | 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用 |
| WO2014186291A1 (en) * | 2013-05-14 | 2014-11-20 | Zoetis Llc | Novel vaccine compositions comprising immunostimulatory oligonucleotides |
| CN105530956A (zh) * | 2013-09-05 | 2016-04-27 | 硕腾服务有限责任公司 | Hendra和Nipah病毒G糖蛋白免疫原性组合物 |
| WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
| PL70842Y1 (pl) * | 2017-08-25 | 2019-06-28 | Gondek Lukasz Kuznia Mocy | Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych |
| AR118202A1 (es) | 2019-02-27 | 2021-09-22 | Univ Rochester | Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US308334A (en) | 1884-11-18 | Ladder | ||
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US5741696A (en) * | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
| FR2702373B1 (fr) * | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
| DE69518316T2 (de) * | 1994-05-10 | 2001-03-29 | American Home Products Corp., Madison | Modifizierter,verbesserter,lebender brsv impfstoff |
| EP1084252B1 (en) | 1998-06-04 | 2006-12-27 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Nucleic acid vaccines for prevention of flavivirus infection |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| CN1549730A (zh) | 2000-10-04 | 2004-11-24 | ���������Ǵ�ѧ�й��� | 黄病毒和瘟病毒衣壳蛋白的组成和使用方法 |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| AU2002305028A1 (en) | 2001-02-28 | 2002-10-28 | Brown University Research Foundation | West nile virus epitopes and uses thereof |
| US20030148261A1 (en) * | 2001-03-12 | 2003-08-07 | Erol Fikrig | Compositions and methods comprising West Nile virus polypeptides |
| US20030104008A1 (en) * | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| FR2823222B1 (fr) * | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| CA2452545C (en) * | 2001-07-27 | 2015-06-09 | Wyeth | West nile vaccine comprising live attenuated, inactivated or killed whole or subunit west nile virus |
| WO2004016586A2 (en) | 2002-08-16 | 2004-02-26 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
-
2002
- 2002-07-23 CA CA2452545A patent/CA2452545C/en not_active Expired - Lifetime
- 2002-07-23 DK DK02806585.2T patent/DK1427444T3/da active
- 2002-07-23 AU AU2002365244A patent/AU2002365244B2/en not_active Expired
- 2002-07-23 MX MXPA04000680A patent/MXPA04000680A/es active IP Right Grant
- 2002-07-23 BR BRPI0211492A patent/BRPI0211492B1/pt active IP Right Grant
- 2002-07-23 PL PL398575A patent/PL220846B1/pl unknown
- 2002-07-23 NZ NZ570270A patent/NZ570270A/en not_active Application Discontinuation
- 2002-07-23 KR KR10-2004-7001202A patent/KR20040028952A/ko not_active Application Discontinuation
- 2002-07-23 ES ES02806585T patent/ES2435095T3/es not_active Expired - Lifetime
- 2002-07-23 PT PT2806585T patent/PT1427444E/pt unknown
- 2002-07-23 KR KR1020097010065A patent/KR20090053967A/ko active Search and Examination
- 2002-07-23 EP EP02806585.2A patent/EP1427444B1/en not_active Expired - Lifetime
- 2002-07-23 CN CN2006101058113A patent/CN1935258B/zh not_active Expired - Lifetime
- 2002-07-23 EP EP10183615A patent/EP2281572A1/en not_active Withdrawn
- 2002-07-23 WO PCT/US2002/023447 patent/WO2003061555A2/en active Application Filing
- 2002-07-23 PL PL368535A patent/PL212212B1/pl unknown
- 2002-07-23 NZ NZ531265A patent/NZ531265A/en not_active IP Right Cessation
- 2002-07-23 HU HU0401606A patent/HU228690B1/hu active Protection Beyond IP Right Term
- 2002-07-23 JP JP2003561501A patent/JP4718778B2/ja not_active Expired - Lifetime
- 2002-07-23 CN CNB028146646A patent/CN1273189C/zh not_active Expired - Lifetime
- 2002-07-23 ME MEP-2008-784A patent/ME00491B/me unknown
- 2002-07-23 RS YU8004A patent/RS53184B/en unknown
- 2002-07-23 EP EP10183676A patent/EP2283858A3/en not_active Ceased
- 2002-07-25 US US10/202,716 patent/US7153513B2/en not_active Expired - Lifetime
-
2004
- 2004-02-26 ZA ZA2004/01596A patent/ZA200401596B/en unknown
- 2004-02-26 HR HRP20040195AA patent/HRP20040195B1/hr not_active IP Right Cessation
- 2004-11-26 HK HK04109356.5A patent/HK1066470A1/xx not_active IP Right Cessation
-
2006
- 2006-10-30 US US11/589,527 patent/US7445787B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,515 patent/US20070166324A1/en not_active Abandoned
- 2006-10-30 US US11/589,523 patent/US20070166326A1/en not_active Abandoned
- 2006-10-30 US US11/589,528 patent/US7648706B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,516 patent/US20070166325A1/en not_active Abandoned
- 2006-10-30 US US11/589,595 patent/US20070231350A1/en not_active Abandoned
- 2006-10-30 US US11/589,507 patent/US7648705B2/en not_active Expired - Lifetime
-
2007
- 2007-02-13 NZ NZ553165A patent/NZ553165A/en not_active IP Right Cessation
-
2010
- 2010-11-15 JP JP2010255105A patent/JP2011057692A/ja active Pending
-
2013
- 2013-10-04 HU HUS1300055C patent/HUS1300055I1/hu unknown
-
2014
- 2014-01-06 LU LU92348C patent/LU92348I2/xx unknown
- 2014-01-31 BE BE2014C006C patent/BE2014C006I2/fr unknown
- 2014-02-20 CY CY2014010C patent/CY2014010I2/el unknown
- 2014-02-21 FR FR14C0016C patent/FR14C0016I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1300055I1 (hu) | West Nile vakcina | |
| IL227966A0 (en) | Vaccination kit | |
| GB0103170D0 (en) | Vaccine composition | |
| GB0103171D0 (en) | Vaccine composition | |
| GB0130215D0 (en) | Vaccine | |
| HUP0402259A3 (en) | Vaccines | |
| GB0407935D0 (en) | Vaccine | |
| IL157498A0 (en) | Vaccine | |
| EP1423141A4 (en) | VACCINE | |
| GB0306611D0 (en) | Novel vaccine | |
| GB0121171D0 (en) | Vaccine | |
| HK1219412A1 (zh) | 對抗尼羅熱病毒的疫苗 | |
| GB0105238D0 (en) | Vaccines | |
| GB0103867D0 (en) | Vaccine | |
| GB0130823D0 (en) | Vaccine | |
| GB0128312D0 (en) | Vaccine | |
| GB0115496D0 (en) | Vaccine | |
| GB0106589D0 (en) | Vaccine | |
| GB0124137D0 (en) | Vaccine | |
| GB0107511D0 (en) | Novel vaccine | |
| GB0104542D0 (en) | Novel vaccine | |
| GB0104538D0 (en) | Novel Vaccine | |
| GB0113552D0 (en) | Vaccines | |
| GB0129338D0 (en) | Vaccination | |
| GB0100512D0 (en) | Vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20220722 |